Bicara Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, has announced its participation in three major upcoming healthcare investor conferences in September 2025.

The company will present at the Cantor Global Healthcare Conference (September 3, 10:55 a.m. ET), the Wells Fargo Healthcare Conference (September 3, 2:15 p.m. ET), and the Morgan Stanley Global Healthcare Conference (September 8, 4:05 p.m. ET). All fireside chat presentations will be available via webcast through Bicara's Investor Relations website.

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that management will participate in multiple upcoming investor conferences:

• Cantor Global Healthcare Conference 2025
  Date and Time: Wednesday, September 3, 2025 at 10:55 a.m. ET

• 2025 Wells Fargo Healthcare Conference
  Date and Time: Wednesday, September 3, 2025 at 2:15 p.m. ET

• Morgan Stanley 23rd Annual Global Healthcare Conference
  Date and Time: Monday, September 8, 2025 at 4:05 p.m. ET

Live webcasts of the fireside chats will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. Replays of the webcasts will be archived and available following each event.

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.

Contacts

Investors
Rachel Frank
IR@bicara.com

Media
Amanda Lazaro
1AB
Amanda@1abmedia.com

FAQ

When is Bicara Therapeutics (BCAX) presenting at the Cantor Global Healthcare Conference 2025?

Bicara Therapeutics will present at the Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at 10:55 a.m. ET.

How can investors access Bicara Therapeutics' (BCAX) conference presentations?

Investors can access live webcasts of the fireside chats through the Investor Relations section of Bicara's website under Events and Presentations. Replays will be available after each event.

What type of company is Bicara Therapeutics (BCAX)?

Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for patients with solid tumors.

Which investor conferences will Bicara Therapeutics (BCAX) attend in September 2025?

Bicara will attend three conferences: the Cantor Global Healthcare Conference, the Wells Fargo Healthcare Conference (both on September 3), and the Morgan Stanley Global Healthcare Conference (September 8).